CTXR (Citius Pharmaceuticals) Beginning Cash Position: $7.72 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

CTXR Citius Pharmaceuticals Inc CTXR
25 GF Score
Price $0.68
! 2 Warning Signs
View Full Analysis

What is Citius Pharmaceuticals Beginning Cash Position?

Citius Pharmaceuticals CTXR +6.28% 25 Beginning Cash Position is $7.72 Mil as of Mar. 2026. GuruFocus rates CTXR with a GF Score™ of 25/100. The stock has 2 warning signs investors should review.

Citius Pharmaceuticals's Beginning Cash Position for the quarter that ended in Mar. 2026 was $7.72 Mil.

Citius Pharmaceuticals's quarterly Beginning Cash Position increased from Sep. 2025 ($0.34 Mil) to Dec. 2025 ($4.25 Mil) and increased from Dec. 2025 ($4.25 Mil) to Mar. 2026 ($7.72 Mil).

Citius Pharmaceuticals's annual Beginning Cash Position declined from Sep. 2023 ($41.71 Mil) to Sep. 2024 ($26.48 Mil) and declined from Sep. 2024 ($26.48 Mil) to Sep. 2025 ($3.25 Mil).

Citius Pharmaceuticals Beginning Cash Position Related Terms

Citius Pharmaceuticals Beginning Cash Position Historical Data

* Premium members only.

The historical data trend for Citius Pharmaceuticals's Beginning Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Citius Pharmaceuticals Beginning Cash Position Chart

Citius Pharmaceuticals Annual Data
Trend Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23 Sep24 Sep25
Beginning Cash Position
Get a 7-Day Free Trial Premium Member Only Premium Member Only 13.86 70.07 41.71 26.48 3.25

Citius Pharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Beginning Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.10 0.03 0.34 4.25 7.72
CTXR
25GF Score
Citius Pharmaceuticals Inc CTXR
Beginning Cash Position is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Citius Pharmaceuticals Beginning Cash Position Calculation

Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement.

What does a Beginning Cash Position of $7.72 Mil mean?
Citius Pharmaceuticals (CTXR) has a Beginning Cash Position of $7.72 Mil as of Mar. 2026. Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement. View historical data on Citius Pharmaceuticals and its competitors.
Is Citius Pharmaceuticals' Beginning Cash Position too high?
Citius Pharmaceuticals' current Beginning Cash Position is $7.72 Mil. Overall, Citius Pharmaceuticals has a GF Score™ of 25/100, reflecting its overall financial health beyond just this single metric.
How does Citius Pharmaceuticals' Beginning Cash Position compare to LEXX and HIND?
Citius Pharmaceuticals' Beginning Cash Position of $7.72 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beginning Cash Position for a Biotechnology company?
A good Beginning Cash Position depends on the Biotechnology industry context. However, Beginning Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beginning Cash Position mean?
A high Beginning Cash Position can signal that a stock is expensive relative to its fundamentals. Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement. View historical data on Citius Pharmaceuticals and its competitors. Citius Pharmaceuticals's current Beginning Cash Position is $7.72 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Citius Pharmaceuticals stock overvalued right now?
Citius Pharmaceuticals (CTXR) has a current Beginning Cash Position of $7.72 Mil. The current Beginning Cash Position is $7.72 Mil. Citius Pharmaceuticals' overall GF Score™ is 25/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beginning Cash Position calculated?
Beginning Cash Position is calculated from a company's financial statements. For Citius Pharmaceuticals (CTXR), the current Beginning Cash Position is $7.72 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Citius Pharmaceuticals Business Description

Address 11 Commerce Drive, First Floor, Cranford, NJ, USA, 07016
Citius Pharmaceuticals Inc is a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, with a focus on oncology, anti-infectives in adjunct cancer care and distinct prescription products. It aims to provide therapeutic products that address unmet medical needs yet have a lower development risk than is usually associated with new chemical entities. The company's flagship product candidate is LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein. It operates through a single operating and reportable segment which is focused on developing and commercializing pioneering targeted oncology therapies.
25GF Score

Get the complete analysis for CTXR

Beginning Cash Position is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.68
Price